JPWO2006057397A1 - (s)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物 - Google Patents
(s)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物 Download PDFInfo
- Publication number
- JPWO2006057397A1 JPWO2006057397A1 JP2006547928A JP2006547928A JPWO2006057397A1 JP WO2006057397 A1 JPWO2006057397 A1 JP WO2006057397A1 JP 2006547928 A JP2006547928 A JP 2006547928A JP 2006547928 A JP2006547928 A JP 2006547928A JP WO2006057397 A1 JPWO2006057397 A1 JP WO2006057397A1
- Authority
- JP
- Japan
- Prior art keywords
- sulfonyl
- fluoroisoquinolin
- methyl
- homopiperazine hydrochloride
- dihydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
すなわち、本発明は、新規な(S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物を提供するものである。
まず、(S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩(1)は、下記式で示される様に特許文献1記載の方法に従って製造できる。
一方、(S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩の無水結晶は、同条件下で経時的に水分含量が増加し、7日後には40%という高い水分含量を示した(図6)。
賦形剤としては、例えば、乳糖、コーンスターチ、白糖、ブドウ糖、ソルビット、結晶セルロースなどが挙げられる。結合剤としては、例えば、ポリビニルアルコール、ポリビニルエーテル、エチルセルロース、メチルセルロース、アラビアゴム、トラガント、ゼラチン、シェラック、ヒドロキシプロピルセルロース、ヒドロキシプロピルスターチ、ポリビニルピロリドンなどが挙げられる。
国際公開第99/20620号パンフレットに記載の方法に従って得られた(S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩(1)2.0gを、水(3mL)に80℃の加温下溶解した。次いで、加温しながらイソプロパノール(12mL)を加え、均一であることを確認した後、一夜室温で放置し結晶化させた。析出した結晶を濾取した後、室温で24時間乾燥し、(S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物1.76g(80.0%)を得た。
理論値:C 45.51%;H 5.86%;N 10.61%;Cl 8.96%
実測値:C 45.50%;H 5.84%;N 10.57%;Cl 8.93%
尚、無水結晶の粉末X線回折パターンを図3に、回折角度、半値幅、d値、強度及び相対強度を表4に示す。
イソプロパノールの代わりにエタノールを使用する以外は実施例1と同様にして、(S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物(2)を製造した。
(S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩(1)50.0gを、水(75mL)に80℃の加温下溶解した。次いで、加温しながらアセトン(300mL)を加え、均一であることを確認した後、一夜室温で放置し結晶化させた。析出した結晶を濾取した後、室温で24時間乾燥し、(S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物(2)45.4g(82.5%)を得た。
元素分析値:C15H18N3O2FS・HCl・2H2Oとして
理論値:C 45.51%;H 5.86%;N 10.61%;Cl 8.96%
実測値:C 45.49%;H 5.82%;N 10.56%;Cl 8.95%
実施例1で得られた本発明の二水和物1gを密封容器内に量り、40、60、80℃の恒温器内で7及び14日間保温し、熱安定性を評価した。結果を表5に示す。
実施例1で得られた本発明の二水和物及び(S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩の無水結晶の各々100mgを秤量瓶に入れ、25℃、33%及び92%RHに保った容器内に開封状態で放置した。次いで、秤量瓶を経時的に秤量し、重量増加を求めることにより、吸湿性を評価した。結果を図6及び7に示す。
実施例3と同様にして本発明の二水和物を更に2ロット製造し、再現性を確認した。結果を表7に示す。
Claims (12)
- (S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物。
- 水分含量が8.80〜9.40%(カールフィッシャー法)である請求項1記載の(S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物。
- 粉末X線回折パターンにおいて、回折角度(2θ)8.660、15.240、17.180、25.100、25.780、26.780、28.100、30.060及び33.200°に特徴的ピークを有する請求項1又は2記載の(S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物。
- 赤外吸収スペクトルにおいて、854、974、1146、1323及び3418cm−1付近に特徴的吸収ピークを有する請求項1〜3のいずれか1項記載の(S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物。
- (S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩を50〜100℃の水に溶解し、次いで親水性有機溶媒を加え、0〜30℃に冷却することを特徴とする請求項1〜4のいずれか1項記載の(S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物の製造方法。
- 水の使用量が、(S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩に対して1.0〜2.0重量倍である請求項5記載の(S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物の製造方法。
- 水と親水性有機溶媒の重量比率が1:2〜1:6である請求項5又は6記載の(S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物の製造方法。
- (S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物及び薬学的に許容される担体を含有する医薬組成物。
- 脳血管障害治療用医薬組成物である請求項8に記載の医薬組成物。
- (S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物を含有する医薬。
- (S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物の、医薬製造のための使用。
- (S)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物の有効量を投与することを特徴とする脳血管障害の予防及び/又は治療方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004344271 | 2004-11-29 | ||
JP2004344271 | 2004-11-29 | ||
PCT/JP2005/021844 WO2006057397A1 (ja) | 2004-11-29 | 2005-11-29 | (s)-(-)-1-(4-フルオロイソキノリン-5-イル)スルホニル-2-メチル-1,4-ホモピペラジン塩酸塩・二水和物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP4016060B2 JP4016060B2 (ja) | 2007-12-05 |
JPWO2006057397A1 true JPWO2006057397A1 (ja) | 2008-06-05 |
Family
ID=36498130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006547928A Active JP4016060B2 (ja) | 2004-11-29 | 2005-11-29 | (s)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物 |
Country Status (24)
Country | Link |
---|---|
US (1) | US7858615B2 (ja) |
EP (1) | EP1818329B1 (ja) |
JP (1) | JP4016060B2 (ja) |
KR (1) | KR101253369B1 (ja) |
CN (1) | CN101068806B (ja) |
AT (1) | ATE465159T1 (ja) |
AU (1) | AU2005308060B2 (ja) |
BR (1) | BRPI0517909B8 (ja) |
CA (1) | CA2589237C (ja) |
CY (1) | CY1112406T1 (ja) |
DE (1) | DE602005020835D1 (ja) |
DK (1) | DK1818329T3 (ja) |
EA (1) | EA011283B1 (ja) |
ES (1) | ES2345562T3 (ja) |
HK (1) | HK1112898A1 (ja) |
MX (1) | MX2007006322A (ja) |
MY (1) | MY139797A (ja) |
NO (1) | NO339021B1 (ja) |
NZ (1) | NZ555560A (ja) |
PL (1) | PL1818329T3 (ja) |
PT (1) | PT1818329E (ja) |
TW (1) | TWI354670B (ja) |
WO (1) | WO2006057397A1 (ja) |
ZA (1) | ZA200704201B (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006290827A (ja) * | 2005-04-13 | 2006-10-26 | Kowa Co | 緑内障予防又は治療剤 |
KR101149954B1 (ko) * | 2005-08-30 | 2012-06-01 | 아사히 가세이 파마 가부시키가이샤 | 술폰아미드 화합물 |
US8415372B2 (en) | 2007-02-27 | 2013-04-09 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
AU2008220104B2 (en) | 2007-02-28 | 2012-09-27 | Asahi Kasei Pharma Corporation | Sulfonamide derivative |
JP5234825B2 (ja) | 2007-07-02 | 2013-07-10 | 旭化成ファーマ株式会社 | スルホンアミド化合物及びその結晶 |
UA102128C2 (en) * | 2008-12-05 | 2013-06-10 | Х. Луннбек А/С | Nalmefene hydrochloride dihydrate |
CN103951624B (zh) | 2010-08-26 | 2019-04-16 | 兴和株式会社 | 1,4-二氮杂环庚烷衍生物或其盐的制造方法 |
KR102177199B1 (ko) * | 2013-04-24 | 2020-11-10 | 고쿠리쓰다이가쿠호진 규슈다이가쿠 | 안저질환 치료제 |
EP3199161B1 (en) * | 2014-09-25 | 2021-12-15 | Kowa Company, Ltd. | Pharmaceutical preparation |
WO2016111688A1 (en) * | 2015-01-08 | 2016-07-14 | Hewlett-Packard Development Company, L.P. | Mobile printers |
CN107216311B (zh) * | 2016-03-21 | 2019-09-03 | 山东诚创医药技术开发有限公司 | (s)-4-[(4-氟代异喹啉-5-基)磺酰基]-3-甲基-1,4-二氮杂环庚烷盐酸盐的精制方法 |
CN106496189A (zh) * | 2016-10-10 | 2017-03-15 | 江苏礼华生物技术有限公司 | 盐酸Ripasudil晶型 |
CN107164328A (zh) * | 2017-06-30 | 2017-09-15 | 太仓卡斯特姆新材料有限公司 | 一种高稳定性mcf‑7乳腺癌细胞的复苏方法 |
BR112021011739A2 (pt) | 2018-12-17 | 2021-08-31 | D. Western Therapeutics Institute, Inc. | Nova forma de isoquinolina sulfonamida |
EP3988544A4 (en) * | 2019-06-21 | 2023-08-09 | Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. | ISOQUINOLINONE DERIVATIVES AS ROCK PROTEIN KINASE INHIBITORS AND THEIR USE |
CN114644618A (zh) | 2020-12-21 | 2022-06-21 | 广州润尔眼科生物科技有限公司 | 一种作为rock蛋白激酶抑制剂的异喹啉酮型化合物的盐型及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3734531B2 (ja) | 1995-06-29 | 2006-01-11 | 旭化成ファーマ株式会社 | 1−(5−イソキノリンスルホニル)ホモピペラジン塩酸塩3水和物 |
EP0870767B1 (en) * | 1995-07-03 | 2000-02-16 | Asahi Kasei Kogyo Kabushiki Kaisha | 1-(5-isoquinolinesulfonyl)homopiperazine hydrochloride hydrates |
KR19990082174A (ko) * | 1996-02-02 | 1999-11-25 | 니뽄 신야쿠 가부시키가이샤 | 이소퀴놀린 유도체 및 의약 |
WO1999020620A1 (fr) * | 1997-10-22 | 1999-04-29 | Nippon Shinyaku Co Ltd | Derive d'isoquinoleine et medicament |
-
2005
- 2005-11-28 MY MYPI20055550A patent/MY139797A/en unknown
- 2005-11-29 AT AT05811715T patent/ATE465159T1/de active
- 2005-11-29 CN CN2005800409718A patent/CN101068806B/zh active Active
- 2005-11-29 ES ES05811715T patent/ES2345562T3/es active Active
- 2005-11-29 CA CA2589237A patent/CA2589237C/en active Active
- 2005-11-29 EP EP05811715A patent/EP1818329B1/en not_active Not-in-force
- 2005-11-29 DE DE602005020835T patent/DE602005020835D1/de active Active
- 2005-11-29 EA EA200701156A patent/EA011283B1/ru not_active IP Right Cessation
- 2005-11-29 KR KR1020077010553A patent/KR101253369B1/ko active Protection Beyond IP Right Term
- 2005-11-29 PT PT05811715T patent/PT1818329E/pt unknown
- 2005-11-29 MX MX2007006322A patent/MX2007006322A/es active IP Right Grant
- 2005-11-29 ZA ZA200704201A patent/ZA200704201B/xx unknown
- 2005-11-29 PL PL05811715T patent/PL1818329T3/pl unknown
- 2005-11-29 US US11/720,288 patent/US7858615B2/en active Active
- 2005-11-29 AU AU2005308060A patent/AU2005308060B2/en not_active Ceased
- 2005-11-29 DK DK05811715.1T patent/DK1818329T3/da active
- 2005-11-29 WO PCT/JP2005/021844 patent/WO2006057397A1/ja active Application Filing
- 2005-11-29 BR BRPI0517909A patent/BRPI0517909B8/pt not_active IP Right Cessation
- 2005-11-29 JP JP2006547928A patent/JP4016060B2/ja active Active
- 2005-11-29 NZ NZ555560A patent/NZ555560A/en unknown
- 2005-11-29 TW TW094141939A patent/TWI354670B/zh active
-
2007
- 2007-05-09 NO NO20072382A patent/NO339021B1/no not_active IP Right Cessation
-
2008
- 2008-02-22 HK HK08101944.7A patent/HK1112898A1/xx not_active IP Right Cessation
-
2010
- 2010-07-16 CY CY20101100669T patent/CY1112406T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4016060B2 (ja) | (s)−(−)−1−(4−フルオロイソキノリン−5−イル)スルホニル−2−メチル−1,4−ホモピペラジン塩酸塩・二水和物 | |
US9902698B2 (en) | 2-[[[2-[(Hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof | |
JP6937322B2 (ja) | 置換ピペリジン化合物の塩 | |
KR100830002B1 (ko) | 시부트라민의 무기산염 | |
KR102402501B1 (ko) | 피마살탄 트로메타민염 및 이를 포함하는 약제학적 조성물 | |
KR101476508B1 (ko) | (S)-베포타스틴 p-톨루엔술폰산염의 신규 결정형 및 이의 제조방법 | |
EP3398946A1 (en) | Salt of morpholine derivative and crystalline form thereof, as well as preparation method, pharmaceutical composition and use of the same | |
KR20070081233A (ko) | 시부트라민 염을 함유하는 약학 조성물 및 이의 제조방법 | |
KR101132949B1 (ko) | 베포타스틴 살리실산염, 이의 제조방법 및 이를 유효성분으로 포함하는 항히스타민 또는 항알레르기용 약학적 조성물 | |
KR20200127480A (ko) | 테네리글립틴 에디실산염 결정형 및 이의 제조방법 | |
KR101507973B1 (ko) | 결정형 베포타스틴 및 그 제조방법 | |
CN113195453A (zh) | 异喹啉磺酰胺的新形态 | |
KR20170134019A (ko) | 신규의 1-[(4-메틸-퀴나졸린-2-일)메틸]-3-메틸-7-(2-부틴-1-일)-8-(3-(r)-아미노-피페리딘-1-일)-크산틴(리나글립틴) 페룰린산염 및 그의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070802 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070802 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20070802 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20070905 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070911 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070914 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100921 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4016060 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110921 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120921 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130921 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S802 | Written request for registration of partial abandonment of right |
Free format text: JAPANESE INTERMEDIATE CODE: R311802 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |